The problem of diabetes with Professor Sarah Ferber of Orgenesis
Professor Sarah Ferber, the chief science officer and the founder of US/Israeli-based Orgenesis joins eHealth Radio & the Diabetes Information Channel. Prof. Ferber's breakthrough discovery suggested that humans carry their own 'stem-cells' throughout adulthood, thus obviating the need for embryonic stem cells for generating an organ in need. Ferber’s research work has been funded over the past 10 years by leading institutions including the Juvenile Diabetes Research Foundation.
Listen to interview [audio player below] with host Eric Michaels & guest Professor Sarah Ferber discuss the following:
How huge is the problem of diabetes? Please explain how the disease affects the pancreas?
How are patients being treated today?
What have your studies proved in this area? Is there major room for improvement?
Please explain what are autologous insulin producing cells? Do we as humans have the power to make our own?
How does the Orgenesis process work?
Professor Sarah Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aaron Ciechanover, winners of the Nobel Prize in Chemistry in 2004. She completed a post-doctoral fellowship at the Joslin Diabetes Center at Harvard Medical School. Prof. Ferber's breakthrough discovery suggested that humans carry their own 'stem-cells' throughout adulthood, thus obviating the need for embryonic stem cells for generating an organ in need. Most of the research was conducted in Prof. Ferber’s lab, in the Endocrine Research Lab at the Sheba Medical Center, and currently employs 11 scientists. Prof. Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research.
Prof. Ferber’s research work has been funded over the past 10 years by the Juvenile Diabetes Research Foundation (JDRF), the Israel Academy of Science foundation (ISF) and D-Cure, a non-profit organization that promotes and funds scientific research in Israel, aimed at finding a cure and better treatments for diabetes (together, over US$4M).